quinazolines has been researched along with ketoconazole in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (35.29) | 29.6817 |
| 2010's | 11 (64.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| del Palacio, A; Garau, M; Pereiro, M | 1 |
| Cano, J; Gené, J; Gilgado, F; Guarro, J; Serena, C | 1 |
| Charoin, JE; Fettner, S; Hamilton, M; Jones, HM; Lum, BL; Pantze, MP; Rakhit, A; Riek, M | 1 |
| Arya, N; Beelen, A; Bowen, CJ; Herendeen, JM; Koch, KM; Smith, DA | 1 |
| Chandler, PA; Huang, HL; Kovarik, JM; Sfikas, N; Slade, A | 1 |
| Beijnen, JH; Rooswinkel, RW; Schinkel, AH; Sparidans, RW; van Herwaarden, AE; van Waterschoot, RA | 1 |
| Hu, A; Muralidhar Reddy, P; Ravinder, V; Rohini, R; Shanker, K | 1 |
| Biller, BM; Tritos, NA | 1 |
| Adamson, D; Brown, K; Chen, E; Evans, TR; Hotte, S; Kollmansberger, C; Lassen, U; Meyer, T; Miller, WH; Nielsen, DL; Rafi, R; Sawyer, MB; Spicer, J | 1 |
| Beumer, JH; Christner, SM; Gramignoli, R; Parise, RA; Pillai, VC; Rudek, MA; Strom, SC; Venkataramanan, R | 1 |
| Hasegawa, T; Higashino, H; Kataoka, M; Masaoka, Y; Matsui, R; Sakuma, S; Yamamoto, M; Yamashita, S | 1 |
| Chen, J; Hu, P; Jiang, J; Liu, D; Zhao, Q; Zheng, X | 1 |
| de Graaf, IA; de Jager, MH; Groothuis, GM; Li, M | 1 |
| Anders, NM; Beumer, JH; Deeken, JF; Rudek, MA; Rusnak, M; Wanjiku, T | 1 |
| Che, J; Li, H; Li, Z; Lu, C; Luo, H; Wang, J; Yang, H; Yue, S; Zhang, T; Zhang, Y; Zhu, M; Zhuang, X | 1 |
| de Graaf, IA; de Jager, MH; Groothuis, GM; Li, M; van de Steeg, E | 1 |
| Allenet, B; Bedouch, P; Bensalah, N; Charpiat, B; Conort, O; Garcia, S; Juste, M; Rose, FX; Roubille, R; Tod, M | 1 |
2 review(s) available for quinazolines and ketoconazole
| Article | Year |
|---|---|
Advances in medical therapies for Cushing's syndrome.
Topics: Animals; Bexarotene; Cushing Syndrome; Etomidate; Humans; Ketoconazole; Lapatinib; Metyrapone; Mifepristone; Mitotane; Quinazolines; Somatostatin; Tetrahydronaphthalenes | 2012 |
[How to act when an alpha-blocker is associated with a potent inhibitor of CYP3A4].
Topics: Adrenergic alpha-Antagonists; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug Therapy, Combination; France; Government Agencies; Humans; Indoles; Ketoconazole; Quinazolines; Sulfonamides; Tamsulosin | 2017 |
3 trial(s) available for quinazolines and ketoconazole
| Article | Year |
|---|---|
The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.
Topics: Adolescent; Adult; Aged; Area Under Curve; Computer Simulation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Erlotinib Hydrochloride; Forecasting; Humans; Ketoconazole; Male; Microsomes, Liver; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2008 |
Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects.
Topics: Adolescent; Adult; Analgesics, Non-Narcotic; Antifungal Agents; Antineoplastic Agents; Area Under Curve; Carbamazepine; Cross-Over Studies; Drug Interactions; Female; Half-Life; Humans; Ketoconazole; Lapatinib; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Young Adult | 2009 |
Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours.
Topics: Adult; Aged; Area Under Curve; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Ketoconazole; Middle Aged; Neoplasms; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Rifampin; Young Adult | 2013 |
12 other study(ies) available for quinazolines and ketoconazole
| Article | Year |
|---|---|
In vitro susceptibilities of Malassezia species to a new triazole, albaconazole (UR-9825), and other antifungal compounds.
Topics: Antifungal Agents; Drug Resistance, Fungal; Fluconazole; Flucytosine; In Vitro Techniques; Itraconazole; Ketoconazole; Malassezia; Microbial Sensitivity Tests; Pyrimidines; Quinazolines; Triazoles; Voriconazole | 2003 |
Antifungal susceptibilities of the species of the Pseudallescheria boydii complex.
Topics: Amphotericin B; Antifungal Agents; Candida; Drug Resistance, Fungal; Echinocandins; Fluconazole; Flucytosine; Humans; Itraconazole; Ketoconazole; Lipopeptides; Lipoproteins; Micafungin; Microbial Sensitivity Tests; Naphthalenes; Peptides, Cyclic; Pseudallescheria; Pyrimidines; Quality Control; Quinazolines; Scedosporium; Terbinafine; Thiazoles; Triazoles; Voriconazole | 2006 |
The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole.
Topics: Administration, Oral; Adult; Antifungal Agents; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Half-Life; Humans; Immunosuppressive Agents; Ketoconazole; Male; Pyrroles; Quinazolines; Young Adult | 2009 |
Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Activators; Enzyme Inhibitors; Gefitinib; Humans; Hydroxylation; Intestines; Ketoconazole; Liver; Male; Mice; Mice, Knockout; Mice, Transgenic; Microsomes; Quinazolines; Species Specificity; Substrate Specificity; Triazolam | 2009 |
Antimicrobial study of newly synthesized 6-substituted indolo[1,2-c]quinazolines.
Topics: Ampicillin; Anti-Bacterial Agents; Antifungal Agents; Bacteria; Fungi; Indoles; Ketoconazole; Microbial Sensitivity Tests; Molecular Structure; Quinazolines; Structure-Activity Relationship | 2010 |
Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer.
Topics: 14-alpha Demethylase Inhibitors; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Erlotinib Hydrochloride; Female; Half-Life; Hepatocytes; HIV Infections; HIV Protease Inhibitors; Humans; Ketoconazole; Male; Middle Aged; Neoplasms; Nucleic Acid Synthesis Inhibitors; Quinazolines; Rifampin; Ritonavir | 2013 |
In vitro-in vivo correlation of the effect of supersaturation on the intestinal absorption of BCS Class 2 drugs.
Topics: Administration, Oral; Albendazole; Animals; Antineoplastic Agents; Calorimetry, Differential Scanning; Cytochrome P-450 CYP3A Inhibitors; Dipyridamole; Drug Stability; Gefitinib; In Vitro Techniques; Intestinal Absorption; Ketoconazole; Male; Quinazolines; Rats; Rats, Sprague-Dawley; Solubility; Solvents; Tubulin Modulators; Vasodilator Agents | 2014 |
Relative contributions of the major human CYP450 to the metabolism of icotinib and its implication in prediction of drug-drug interaction between icotinib and CYP3A4 inhibitors/inducers using physiologically based pharmacokinetic modeling.
Topics: Antineoplastic Agents; Area Under Curve; Computer Simulation; Crown Ethers; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Humans; Ketoconazole; Male; Microsomes, Liver; Models, Biological; Quinazolines; Rifampin | 2015 |
Rat precision-cut intestinal slices to study P-gp activity and the potency of its inhibitors ex vivo.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Cyclosporins; In Vitro Techniques; Intestinal Mucosa; Isoquinolines; Ketoconazole; Male; Quinazolines; Quinidine; Rats, Wistar; Rhodamine 123; Verapamil | 2015 |
Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib.
Topics: Administration, Oral; Alkynes; Animals; Anti-Retroviral Agents; Antineoplastic Agents; Benzoxazines; Biological Availability; Biotransformation; Cyclopropanes; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Dexamethasone; Drug Evaluation, Preclinical; Drug Interactions; Erlotinib Hydrochloride; Half-Life; Ketoconazole; Male; Metabolic Clearance Rate; Mice, Inbred Strains; Protein Kinase Inhibitors; Quinazolines; Ritonavir | 2015 |
Allosteric activation of midazolam CYP3A5 hydroxylase activity by icotinib - Enhancement by ketoconazole.
Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Crown Ethers; Cytochrome P-450 CYP3A; Dogs; Dose-Response Relationship, Drug; Drug Interactions; Haplorhini; Humans; In Vitro Techniques; Ketoconazole; Mice; Microsomes, Liver; Midazolam; Quinazolines; Rats; Species Specificity; Substrate Specificity | 2016 |
The consequence of regional gradients of P-gp and CYP3A4 for drug-drug interactions by P-gp inhibitors and the P-gp/CYP3A4 interplay in the human intestine ex vivo.
Topics: Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily B, Member 1; Colon; Cyclosporins; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Humans; Ileum; In Vitro Techniques; Isoquinolines; Jejunum; Ketoconazole; Male; Middle Aged; Quinazolines; Quinidine; Verapamil | 2017 |